Dipankar Ray1, Paramita Ray2, Daysha Ferrer-Torres3, Zhuwen Wang3, Derek Nancarrow3, Hee-Won Yoon3, May San Martinho2, Tonaye Hinton2, Scott Owens4, Dafydd Thomas4, Hui Jiang5, Theodore S Lawrence2, Jules Lin3, Kiran Lagisetty3, Andrew C Chang3, David G Beer6. 1. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. Electronic address: dipray@umich.edu. 2. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. 3. Department of Surgery, Thoracic Surgery, University of Michigan, Ann Arbor, Michigan. 4. Department of Pathology, University of Michigan, Ann Arbor, Michigan. 5. Department of Biostatistics, University of Michigan, Ann Arbor, Michigan. 6. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; Department of Surgery, Thoracic Surgery, University of Michigan, Ann Arbor, Michigan. Electronic address: dgbeer@umich.edu.
Abstract
BACKGROUND & AIMS: Barrett's esophagus (BE) can progress to dysplasia and esophageal adenocarcinoma (EAC), accompanied by mutations in TP53 that increase the stability of its product, p53. We analyzed BE tissues for messenger RNAs (mRNAs) that associate with BE progression and identified one that affects the stabilization of p53. METHODS: We obtained 54 BE samples collected from patients with high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC), from 1992 through 2015, and performed RNA sequence analyses, including isoform-specific analyses. We performed reverse-transcription polymerase chain reaction analyses of 166 samples and immunohistochemical analyses of tissue microarrays that contained BE tissues from 100 patients with HGD or EAC and normal esophageal squamous mucosa (controls). Proteins were expressed from transfected plasmids or knocked down with small interfering RNAs in BE cells and analyzed by immunoblots and in immunoprecipitation and ubiquitin ligase assays. Athymic nude mice bearing EAC xenograft tumors (grown from OE-33 cells) were given intraperitoneal injections of simvastatin; tumor growth was monitored and tumors were collected and analyzed by immunoblotting for levels of RNF128, p53, and acetylated p53. RESULTS: Progression of BE to HGD or EAC associated with changes in expression of mRNAs that encoded mucins and promoted inflammation and activation of ATM and the DNA damage response. As tissues progressed from BE to HGD to EAC, they increased expression of mRNAs encoding isoform 1 of RNF128 (Iso1) and decreased expression of Iso2 of RNF128. RNF128 is an E3 ubiquitin ligase that targets p53 for degradation. Incubation of BE cells with interferon gamma caused them to increase expression of Iso1 and reduce expression of Iso2. Iso1 was heavily glycosylated with limited ubiquitin ligase activity for p53, resulting in p53 stabilization. Knockdown of Iso1 in BE and EAC cells led to degradation of the mutant form of p53 and reduced clonogenic survival. In contrast, Iso2 was a potent ligase that reduced levels of the mutant form of p53 in BE cells. In BE cells, Iso2 was hypoglycosylated and degraded, via ATM and GSK3β-mediated phosphorylation and activation of the beta-TrCP1-containing SCF ubiquitin ligase complex. Simvastatin, which degrades the mutant form of p53, also degraded RNF128 Iso1 protein in BE cells and slowed growth of EAC xenograft tumors in mice. CONCLUSIONS: We found that isoform 2 of RNF128 is decreased in BE cells, resulting in increased levels of mutant p53, whereas isoform 1 of RNF128 is increased in BE cells, further promoting the stabilization of mutant p53.
BACKGROUND & AIMS: Barrett's esophagus (BE) can progress to dysplasia and esophageal adenocarcinoma (EAC), accompanied by mutations in TP53 that increase the stability of its product, p53. We analyzed BE tissues for messenger RNAs (mRNAs) that associate with BE progression and identified one that affects the stabilization of p53. METHODS: We obtained 54 BE samples collected from patients with high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC), from 1992 through 2015, and performed RNA sequence analyses, including isoform-specific analyses. We performed reverse-transcription polymerase chain reaction analyses of 166 samples and immunohistochemical analyses of tissue microarrays that contained BE tissues from 100 patients with HGD or EAC and normal esophageal squamous mucosa (controls). Proteins were expressed from transfected plasmids or knocked down with small interfering RNAs in BE cells and analyzed by immunoblots and in immunoprecipitation and ubiquitin ligase assays. Athymic nude mice bearing EAC xenograft tumors (grown from OE-33 cells) were given intraperitoneal injections of simvastatin; tumor growth was monitored and tumors were collected and analyzed by immunoblotting for levels of RNF128, p53, and acetylated p53. RESULTS: Progression of BE to HGD or EAC associated with changes in expression of mRNAs that encoded mucins and promoted inflammation and activation of ATM and the DNA damage response. As tissues progressed from BE to HGD to EAC, they increased expression of mRNAs encoding isoform 1 of RNF128 (Iso1) and decreased expression of Iso2 of RNF128. RNF128 is an E3 ubiquitin ligase that targets p53 for degradation. Incubation of BE cells with interferon gamma caused them to increase expression of Iso1 and reduce expression of Iso2. Iso1 was heavily glycosylated with limited ubiquitin ligase activity for p53, resulting in p53 stabilization. Knockdown of Iso1 in BE and EAC cells led to degradation of the mutant form of p53 and reduced clonogenic survival. In contrast, Iso2 was a potent ligase that reduced levels of the mutant form of p53 in BE cells. In BE cells, Iso2 was hypoglycosylated and degraded, via ATM and GSK3β-mediated phosphorylation and activation of the beta-TrCP1-containing SCF ubiquitin ligase complex. Simvastatin, which degrades the mutant form of p53, also degraded RNF128 Iso1 protein in BE cells and slowed growth of EAC xenograft tumors in mice. CONCLUSIONS: We found that isoform 2 of RNF128 is decreased in BE cells, resulting in increased levels of mutant p53, whereas isoform 1 of RNF128 is increased in BE cells, further promoting the stabilization of mutant p53.
Authors: Austin M Dulak; Steven E Schumacher; Jasper van Lieshout; Yu Imamura; Cameron Fox; Byoungyong Shim; Alex H Ramos; Gordon Saksena; Sylvan C Baca; Jose Baselga; Josep Tabernero; Jordi Barretina; Peter C Enzinger; Giovanni Corso; Franco Roviello; Lin Lin; Santhoshi Bandla; James D Luketich; Arjun Pennathur; Matthew Meyerson; Shuji Ogino; Ramesh A Shivdasani; David G Beer; Tony E Godfrey; Rameen Beroukhim; Adam J Bass Journal: Cancer Res Date: 2012-07-02 Impact factor: 12.701
Authors: Shirish Shukla; Uday Sankar Allam; Aarif Ahsan; Guoan Chen; Pranathi Meda Krishnamurthy; Katherine Marsh; Matthew Rumschlag; Sunita Shankar; Christopher Whitehead; Matthew Schipper; Venkatesha Basrur; Daniel R Southworth; Arul M Chinnaiyan; Alnawaz Rehemtulla; David G Beer; Theodore S Lawrence; Mukesh K Nyati; Dipankar Ray Journal: Neoplasia Date: 2014-02 Impact factor: 5.715
Authors: Austin M Dulak; Petar Stojanov; Shouyong Peng; Michael S Lawrence; Cameron Fox; Chip Stewart; Santhoshi Bandla; Yu Imamura; Steven E Schumacher; Erica Shefler; Aaron McKenna; Scott L Carter; Kristian Cibulskis; Andrey Sivachenko; Gordon Saksena; Douglas Voet; Alex H Ramos; Daniel Auclair; Kristin Thompson; Carrie Sougnez; Robert C Onofrio; Candace Guiducci; Rameen Beroukhim; Zhongren Zhou; Lin Lin; Jules Lin; Rishindra Reddy; Andrew Chang; Rodney Landrenau; Arjun Pennathur; Shuji Ogino; James D Luketich; Todd R Golub; Stacey B Gabriel; Eric S Lander; David G Beer; Tony E Godfrey; Gad Getz; Adam J Bass Journal: Nat Genet Date: 2013-03-24 Impact factor: 38.330
Authors: Kiran H Lagisetty; Dyke P McEwen; Derek J Nancarrow; Johnathon G Schiebel; Daysha Ferrer-Torres; Dipankar Ray; Timothy L Frankel; Jules Lin; Andrew C Chang; Laura A Kresty; David G Beer Journal: JCI Insight Date: 2021-01-11
Authors: Yun Zhang; Katherine M Weh; Connor L Howard; Jean-Jack Riethoven; Jennifer L Clarke; Kiran H Lagisetty; Jules Lin; Rishindra M Reddy; Andrew C Chang; David G Beer; Laura A Kresty Journal: Mol Ther Nucleic Acids Date: 2022-08-17 Impact factor: 10.183